Goldman Sachs Group Inc. Has $238.32 Million Position in Roivant Sciences Ltd. $ROIV

Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 365.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 10,982,633 shares of the company’s stock after buying an additional 8,621,567 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Roivant Sciences were worth $238,323,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. lifted its holdings in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares during the period. Jones Financial Companies Lllp lifted its holdings in Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after buying an additional 1,148 shares during the period. Allworth Financial LP lifted its holdings in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Bessemer Group Inc. lifted its holdings in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Finally, Clearstead Advisors LLC lifted its holdings in Roivant Sciences by 141.6% during the 4th quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock worth $63,000 after buying an additional 1,704 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $28.58 on Friday. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $32.79. The firm has a market capitalization of $20.56 billion, a price-to-earnings ratio of -47.63 and a beta of 1.13. The business has a 50-day simple moving average of $28.76 and a 200 day simple moving average of $25.67.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The business had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. During the same period in the previous year, the company posted ($0.29) EPS. On average, sell-side analysts expect that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Analyst Upgrades and Downgrades

ROIV has been the topic of several recent research reports. Sanford C. Bernstein initiated coverage on Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 target price on the stock. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Leerink Partners set a $42.00 price objective on Roivant Sciences in a research note on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, TD Cowen boosted their price objective on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.59.

Insider Transactions at Roivant Sciences

In related news, Director Melissa B. Epperly sold 41,861 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the completion of the sale, the director directly owned 15,804 shares of the company’s stock, valued at $453,258.72. The trade was a 72.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00. Following the sale, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at $48,827,417.01. This represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 945,173 shares of company stock valued at $27,654,456. 10.80% of the stock is currently owned by corporate insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.